Oscient initiated by Thomas Weisel at outperform

Oscient Pharmaceuticals Inc. coverage was initiated by Thomas Weisel Partners analyst Joe Slavinsky at an outperform rating with a current value range on the stock of $4 to $7 per share. Thomas Weisel believes that a significantly expanded salesforce and a potentially broader label will drive sales of Factive beginning this respiratory infection season (fall/winter) and continuing thereafter. Oscient shares Wednesday were unchanged at $2.30 on volume of 2,997,104 shares versus the three-month running average of 724,511 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.